Susan Wakil School of Nursing and Midwifery, University of Sydney, Sydney, Australia.
Nuffield Department of Surgical Sciences and Biomedical Research Centre, University of Oxford, Oxford, UK.
BMC Cancer. 2022 Apr 22;22(1):442. doi: 10.1186/s12885-022-09539-8.
Oral mucositis (OM) is known to be the most common and challenging side effect of conditioning chemotherapy in haematopoietic cell transplant (HCT). This side effect causes significant morbidity and may delay the treatment plan, as well as increase therapeutic expenses. There are few clinical trials in the literature that indicate any kind of treatment or prevention methods are effective. Therefore, the aim of this study is to perform a systematic review of literature and examine the effectiveness of oral cryotherapy (OC) in management of chemotherapy-induced OM in patients with haematological malignancies undergoing a HCT.
A systematic literature search was conducted, using the electronic databases PubMed, Embase, MEDLINE and Scopus. A total of 322 papers were identified and 9 papers were analysed based on defined inclusion and exclusion criteria. The quality of the chosen primary studies was appraised using the COCHRANE risk of bias assessment tool.
Nine randomized controlled trials, analysing 658 participants; control group (n = 289, age mean ± SD; 41.15 ± 21) and treatment group (n = 369, age mean ± SD; 39.15 ± 20), were included in this systematic review. Seven studies had significantly addressed the effectiveness of OC (p value < 0.05), in reducing the incidence of developing severe OM in the adult population undergoing HCT, especially when the conditioning regimen protocols included high dose of alkylating agent such as melphalan.
This review supports the use of OC for prevention of OM in patients undergoing HCT, with high-dose of melphalan conditioning protocols. It is recommended that more studies be conducted to compare efficacy and duration of OC with other chemotherapeutic agents with relatively short plasma half-lives. The heterogeneity of the trials demonstrated the need to regulate the validated assessment tools and similar interventions that would enable comparisons and analyses of treatment effects based on well-designed RCTs.
口腔黏膜炎(OM)是造血细胞移植(HCT)中预处理化疗最常见且极具挑战性的副作用。这种副作用会导致显著的发病率,可能会延迟治疗计划,并增加治疗费用。文献中的临床试验很少表明任何治疗或预防方法是有效的。因此,本研究旨在对文献进行系统回顾,并检查口腔冷冻疗法(OC)在管理接受 HCT 的血液恶性肿瘤患者化疗诱导的 OM 中的有效性。
使用电子数据库 PubMed、Embase、MEDLINE 和 Scopus 进行系统文献检索。共确定了 322 篇论文,并根据明确的纳入和排除标准分析了 9 篇论文。使用 COCHRANE 偏倚风险评估工具评估选定的原始研究的质量。
纳入了 9 项随机对照试验,分析了 658 名参与者;对照组(n=289,年龄均值±标准差;41.15±21)和治疗组(n=369,年龄均值±标准差;39.15±20)。7 项研究显著解决了 OC(p 值<0.05)在降低接受 HCT 的成人人群中严重 OM 发生率方面的有效性,尤其是在预处理方案包括高剂量烷化剂(如美法仑)时。
本综述支持在接受 HCT 且接受高剂量美法仑预处理方案的患者中使用 OC 预防 OM。建议进行更多研究,以比较 OC 与其他半衰期相对较短的化疗药物的疗效和持续时间。试验的异质性表明有必要规范经过验证的评估工具和类似干预措施,以便能够根据精心设计的 RCT 比较和分析治疗效果。